MPLT earnings: next report 2026-09-18, real EPS beat/miss history, analyst consensus Buy, P/E -7.71. Updated 2026-07-23.
MapLight Therapeutics (MPLT) Research Hub
MapLight Therapeutics (MPLT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 13 USD (-5.18%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -7.71, market cap 0.03B. This hub links to the full technical, earnings and options research available for MPLT.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 13 USD (-5.18%) |
| 52-week range | 9.1 USD – 39.91 USD |
| Trend regime | Range |
| 14-day RSI | 55.7 (Bullish) |
| Trailing P/E | -7.71 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
| Next earnings | 2026-09-18 |
Available research for MPLT
Covered Call on MPLT: how it works, illustrative setup around the real 13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on MPLT: how it works, illustrative setup around the real 13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on MPLT: how it works, illustrative setup around the real 13 USD price, max profit/loss, breakeven and when to use it. Educational.
MPLT technical analysis: range, last 13 USD, RSI 55.7, 52w range 9.1 USD–39.91 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is MPLT in?
MapLight Therapeutics (MPLT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is MPLT in an uptrend or downtrend?
As of 2026-09-11, MPLT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is MPLT's trailing P/E ratio?
MPLT's trailing P/E is -7.71, with a market cap of 0.03B. See the earnings research page for full valuation detail.
When does MPLT next report earnings?
MPLT is next scheduled to report earnings on 2026-09-18, with a consensus EPS estimate of -1.32414 USD.